This phenomenon may be associated with an increased mutational burden in NB cells which combined with blockade of topoisomerases by Topotecan, may further increase the mutational burden, supporting the hypothesis that SGSS05-NS3 or UNC0379 treatment in combination with Topotecan may potentially have a synthetic lethality effect [44–47]. Here, KRAS is linked to neuroblastoma.